Age-related decline in dopamine transporter in human brain using PET with a new radioligand [18F]FE-PE2I

Annals of Nuclear Medicine

Volumn 28, Issue 3, 2014, Pages 220-226

  Shingai, Yoshitoshi ^a   Tateno, Amane ^a   Arakawa, Ryosuke ^a,b   Sakayori, Takeshi ^a   Kim, Woochan ^a   Suzuki, Hidenori ^a   Okubo, Yoshiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Aging; Dopamine transporter (DAT); Human; Positron emission tomography (PET)

Indexed keywords

DOPAMINE TRANSPORTER; N (3 IODOPROP 2 ENYL) 2BETA CARBOFLUOROETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE F 18; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CEREBELLUM CORTEX; DENSITY; FEMALE; HUMAN; MALE; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; THALAMUS;

EID: 84900819233     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0798-1     Document Type: Article

References (43)

1. Chou KL, Bohnen NI. Performance on an Alzheimer-selective odor identification test in patients with Parkinson's disease and its relationship with cerebral dopamine transporter activity. Parkinsonism Relat Disord. 2009;15(9):640-3.
2. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39(9):1521-30. (Pubitemid 28459879)
3. Oh M, Kim JS, Kim JY, Shin K-H, Park SH, Kim HO, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53(3):399-406.
4. Ginovart N, Lundin A, Farde L, Halldin C, Bäckman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 1997;120(Pt 3):503-14. (Pubitemid 27153642)
5. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57(3):229-38. (Pubitemid 40187366)
6. Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry. 2010;67(1):59-68.
7. Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, et al. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res. 2009;43(15): 1219-23.
8. Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse. 2009;63(4):282-90.
9. Rinne JO, Sahlberg N, Ruottinen H, Någren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology. 1998;50(1):152-6.
10. Troiano AR, Schulzer M, de la Fuente-Fernandez R, Mak E, McKenzie J, Sossi V, et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse. 2010;64(2):146-51.
11. Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, Mac-Gregor R, et al. Decreased dopamine transporters with age in health human subjects. Ann Neurol. 1994;36(2):237-9. (Pubitemid 24239243)
12. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37(4):554-9. (Pubitemid 126618439)
13. Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol. 1998;44(1):143-7. (Pubitemid 28323668)
14. Allard P, Marcusson JO. Age-correlated loss of dopamine uptake sites labeled with [3H]GBR-12935 in human putamen. Neurobiol Aging. 1989;10(6):661-4. (Pubitemid 20059498)
15. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 1990; 27(2):157-61. (Pubitemid 20086635)
16. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol. 1998;401(2):253-65. (Pubitemid 28481965)
17. Hebert MA, Larson GA, Zahniser NR, Gerhardt GA. Age-related reductions in [3H]WIN 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the fischer 344 rat. J Pharmacol Exp Ther. 1999;288(3):1334-9. (Pubitemid 29254175)
18. Zelnik N, Angel I, Paul SM, Kleinman JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol. 1986;126(1-2):175-6. (Pubitemid 16014752)
19. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4(4):371-7. (Pubitemid 20044793)
20. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse. 1993;15(2):130-42. (Pubitemid 23311584)
21. Farde L, Halldin C, Müller L, Suhara T, Karlsson P, Hall H. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse. 1994;16(2):93-103.
22. Ding YS, Fowler JS, Volkow ND, Gatley SJ, Logan J, Dewey SL, et al. Pharmacokinetics and in vivo specificity of [11C]dl-threomethylphenidate for the presynaptic dopaminergic neuron. Synapse. 1994;18(2):152-60. (Pubitemid 24308132)
23. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Hietala J. [18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse. 1998;28(3):244-50. (Pubitemid 28086839)
24. Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44(6): 855-61. (Pubitemid 39663394)
25. Halldin C, Erixon-Lindroth N, Pauli S, Chou Y-H, Okubo Y, Karlsson P, et al. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30(9):1220-30. (Pubitemid 37205375)
26. Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63(10):871-80.
27. Ito H, Sudo Y, Suhara T, Okubo Y, Halldin C, Farde L. Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D(2) dopamine receptors in the human brain. Neuroimage. 2001;13(3):531-9. (Pubitemid 34185011)
28. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3 Pt 1):153-8.
29. Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med. 2012;53(7):1065-73.
30. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-9. (Pubitemid 47301451)
31. Kula NS, Baldessarini RJ, Tarazi FI, Fisser R, Wang S, Trometer J, et al. [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol. 1999;385(2-3):291-4.
32. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3′,4′- disubstituted phenyl)nortropane. New high-affinity and selective compound. J Med Chem. 1997;40(9):1366-72. (Pubitemid 27198083)
33. Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33(6):657-68. (Pubitemid 43846756)
34. Odano I, Varrone A, Savic I, Ciumas C, Karlsson P, Jucaite A, et al. Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter-application to juvenile myoclonic epilepsy. Neuroimage. 2012;59(4):3582-93.
35. Seki C, Ito H, Ichimiya T, Arakawa R, Ikoma Y, Shidahara M, et al. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Ann Nucl Med. 2010;24(4): 249-60.
36. Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28(5):1059-69. (Pubitemid 351589643)
37. Shetty HU, Zoghbi SS, Liow J-S, Ichise M, Hong J, Musachio JL, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I. Eur J Nucl Med Mol Imaging. 2007;34(5):667-78. (Pubitemid 46669359)
38. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-301.
39. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1991; 54(5):388-96.
40. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318(14):876-80. (Pubitemid 18090271)
41. Cosgrove KP, Mazure CM, Staley JK. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatry. 2007;62(8):847-55. (Pubitemid 47488220)
42. Miller IN, Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord. 2010;25(16):2695-703.
43. Hagemeier J, Dwyer MG, Bergsland N, Schweser F, Magnano CR, Heininen-Brown M, et al. Effect of age on MRI phase behavior in the subcortical deep gray matter of healthy individuals. AJNR Am J Neuroradiol. 2013;34:2144-51.